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Introduction
Tanapox virus (TPV) is a member of the Yatapoxvirus genus of poxviruses that is characterized by its ability to cause relatively mild monkeypox-like infections of primates, including man (Damon, 2007; Knight et al., 1989) . TPV is endemic to equatorial Africa and causes occasional zoonotic infections in humans, likely transmitted through biting arthropod vectors, but direct human-to-human transmission of TPV has never been observed. TPV infection begins with brief febrile illness, followed by the development of one or few inflamed nodulelike lesions and concurrent lymphadenopathy. Maximum lesion size is reached by approximately 2 weeks and resolution of the lesion usually occurs within 6 weeks (Jezek et al., 1985) .
This self-limiting poxvirus infection is contrasted with Variola virus (VARV), which causes smallpox and is a systemic disease of comparatively short duration with significant morbidity and mortality (Damon, 2007) . From the study of other orthopoxviruses, it is likely that VARV, like other orthopoxviruses, spreads from the initial site of infection (usually the skin or respiratory route), through infected dendritic cells that traffic to the draining lymph node (Damon, 2007) . Primary viremia is caused by viral replication within the lymph node and causes subsequent infection of secondary sites through the blood, including the spleen, liver, and bone marrow. Secondary viremia from these sites causes other localized infections, which leads to the characteristic pock lesions or rash (Damon, 2007) . Studies with Vaccinia Available online at www.sciencedirect.com Virology 368 (2007) 32 -40 www.elsevier.com/locate/yviro virus (VACV) suggest that monocytes and activated T-cells are the main targets of orthopoxvirus replication within the blood and may be primarily responsible for systemic spread of the highly pathogenic poxviruses (Chahroudi et al., 2005; SanchezPuig et al., 2004; Yu et al., 2006) . Both the dermal and epidermal layers of the skin have been implicated in pock formation, with viral replication within the dermal layer being important for systemic spread of the virus from the periphery (Damon, 2007) . At the other end of the pathogenic spectrum of poxviruses in man lies Molluscum contagiosum virus (MOCV), for which viral replication is highly restricted to differentiating keratinocytes, resulting in small benign lesions as the only clinical feature in immunocompetent hosts (Gottlieb and Myskowski, 1994; Lewis et al., 1997) . Lesions may persist for months without any immune cell infiltrate and, as a result, are noted for a lack of inflammation at sites of viral infection (Heng et al., 1989) .
Findings from these viruses suggests that cellular tropism of poxviruses that infect man may be closely linked to its pathogenicity. Poxvirus tropism of cultured cells is largely mediated at the intracellular level and it is generally accepted that poxviruses, through receptor non-specific interactions, are able to bind and enter most cell types and express at least some early gene products (Moss, 2006) . In fact, resting human naive T-cells are one of the few cell types which have been reported to be refractory to the binding and/or entry of vaccinia virus (Chahroudi et al., 2005) . Permissiveness of poxviruses is therefore thought to be controlled at the level of the intracellular environment, which varies based on cell type, cellular activation state, and various induced anti-viral signaling cascades (McFadden, 2005) . A successful poxvirus infection regulates the intracellular signaling environment of the infected cell to ensure both the efficient transcription and translation of viral genes that lead to the production of progeny virions, and also to mitigate the various anti-viral cellular responses.
One of the most intricately regulated cell processes is the cell cycle, in which chromosomes are replicated (S) and then are segregated into two daughter cells through mitosis (M). Regulatory checkpoints at G0, G1, and G2, allow for rigorous control of replication through the cell cycle (reviewed by Murray, 2004) . Many viruses favor cells in a certain phase of the cell cycle in order to provide an adequate environment for viral replication. As such, stimulating progression through the cell cycle is a key adaptive strategy for many viruses, including cytomegalovirus (Castillo and Kowalik, 2004) , adenovirus (Berk, 2005) , and poxviruses (Johnston et al., 2005; Wali and Strayer, 1999) . For example, VACV infection can increase transit of cells out of G1 into S phase through a modulation of cyclin and cyclin-dependent kinase levels (Wali and Strayer, 1999) . Similarly, the Myxoma virus (MYXV) M-T5 host range protein has been shown to interact with host cell cullin-1, and a MYXV construct deficient in M-T5 was shown to be unable to transition infected cells out of cell cycle arrest, correlating with a reduction in MYXV replication (Johnston et al., 2005) .
The current study was initiated to analyze TPV infection in primary human cells to correlate its cellular tropism in human cells ex vivo to its pathogenicity profile in man. A TPV expressing EGFP from a synthetic early/late poxvirus promoter was constructed to aid in the identification of TPVinfected cells, which was used to assess replication efficiencies in primary human cells in vitro. Various modulations of cell states were also tested, including differentiation, activation, and cell cycle arrest induced by treatment with cytostatic drug rapamycin, to evaluate their role in TPV replication. The cellular tropism profile of TPV in primary human cells is discussed as a potential ex vivo surrogate system to rationalize the restricted spread of TPV throughout the infected host and better understand its self-limiting pathogenesis profile in man.
Results

Optimal replication temperature of TPV-GFP is 33-35°C
TPV was engineered to express EGFP from a synthetic early/late promoter. An expression cassette containing the synthetic early/late promoter and EGFP open reading frame was inserted between 5L and 6L in the TPV genome. TPV 5L is predicted to encode a ubiquitin ligase and TPV 6L is of unknown function. TPV-GFP was plaque purified and verified to be pure by PCR analysis of the viral genomic DNA (data not shown). It has been previously reported that TPV grows equally well at both 33°C and 37°C, reaching a maximum titer at 96 h post-infection (hpi), in OMK cells (Mediratta and Essani, 1999 ). However, when tested in OMK cells, single step replication curves of TPV at 33°C and 37°C show a decrease in virus progeny at late time points only at the higher temperature (Fig. 1A ). Single step replication curves were repeated for TPV-GFP and were carried out at three temperatures: 33°C, 35°C, and 37°C. TPV-GFP grows poorly, if at all, at 37°C; however, at both 33°C and 35°C, TPV-GFP replicates productively with an approximate 2-log increase in infectious progeny (Fig. 1B) . Since TPV-GFP replication appears to be highly sensitive to temperature, subsequent experiments with primary human cells were performed at 33°C.
Cycling, but not growth arrested, primary human dermal fibroblasts are permissive for TPV-GFP We observed that primary human dermal fibroblasts (pHDFs) that had reached confluence and were in a quiescent state supported only low levels of TPV-GFP replication, accompanied by reduced GFP expression. To investigate this further, pHDFs, either growing exponentially or quiescent, were infected with TPV-GFP at an MOI of 3 and TPV replication kinetics were analyzed over 4 days. Virus from the indicated time points was collected and titrated on OMK cells (Fig. 2) . A 40-fold decrease in progeny virus yield was observed from the quiescent HDFs as compared to exponentially growing pHDFs. To further investigate the idea that cycling pHDFs are required for optimal TPV replication, pHDFs treated with the drug rapamycin were used. Rapamycin is a highly specific inhibitor of mTOR and treatment with this drug causes arrest in the G1 stage of cell cycle in many types of cells, including pHDFs (Inoki and Guan, 2006) . Virus replication in cells treated with rapamycin was found to be particularly restricted, especially at early time points, but reaches a final level similar to quiescent pHDFs by 4 days postinfection (Fig. 2) . Interestingly, rapamycin has recently been shown to have the opposite effect on the virus replication of another poxvirus, myxoma virus, in human cancer cells that have altered intracellular signaling pathways (Stanford et al., 2007) . In contrast, TPV is non-permissive in these particular human cancer cell lines (data not shown).
In order to quantify the cell cycle changes caused by these treatments, cells were collected, genomic DNA was stained with propidium iodide, and cells were analyzed by FACS (Fig.  3A) . Prior to infection, growing pHDFs showed a typical distribution in the cell cycle, with G1 being the majority, and the rest of the cells in S or G2. Infection of cycling pHDFs caused an increase in the number of cells in the S and G2 phases of the cell cycle, implying that TPV infection stimulates cell cycle progression. In contrast, both quiescent cells and pHDFs treated with rapamycin accumulated in the G1 phase prior to infection. After TPV infection, quiescent cells accumulated in early S phase but did not proceed through the cell cycle to accumulate in G2. Cells treated with rapamycin, however, did not seem to experience any significant change over the time of the experiment, a consequence of their drug induced arrest in G1 that the virus is unable to reverse (Fig. 3A) . Growth phase distribution of uninfected cells did not vary over the course of the experiment (Fig. 3B) .
Multistep replication curves were also performed with growing and quiescent pHDFs to examine the effect of cellular cycling on TPV cell-to-cell spread. The inherent infectivity of the virus was not grossly compromised in the quiescent pHDF since a comparable number of GFP positive foci of infection are present in both treatments (Fig. 4A) . As in the single step replication curves, TPV propagation in the growing and quiescent pHDFs followed similar early kinetics of growth up to 48 hpi and then a decrease in subsequent progeny titers was detected (Fig. 4B) . However, there was reduced fluorescence intensity of the GFP and smaller foci in the quiescent pHDFs as compared to growing pHDFs (Fig. 4A) . Additionally, the cytopathic effect of the virus in the quiescent cells was markedly reduced, even at day 7 (Fig. 4A) . To quantify the difference in infection and fluorescence intensity, pHDFs at 7 days post-infection were analyzed by FACS. Growing pHDFs were over 98% positive for GFP expression and had a mean fluorescence intensity of over 1500. However, infected quiescent pHDFs were approximately 60% positive for GFP expression, with a mean fluorescence intensity of below 200 (Fig. 4C) . Fig. 2 . Cell cycle blockade inhibits TPV-GFP replication in primary HDFs. Primary HDFs were either growing, quiescent through contact-mediated inhibition or pretreated with rapamycin (20 nM) for 16 h when they were infected with TPV-GFP at an MOI of 3. Cells were collected at the indicated time points and samples were titrated in triplicate on OMK cells. 
CD14+ cells are the primary target of TPV-GFP infection in PBMCs
To further this avenue of investigating infection in primary cells, human peripheral blood mononuclear cells (PBMCs) were freshly isolated from donors, purified, and infected with TPV-GFP at an MOI of 3. Cells were harvested at 24 and 72 hpi, stained for CD3 and CD14, markers of T-cells and monocytes, respectively, and analyzed by FACS (Fig. 5) . CD14+ cells were the main target of infection for TPV-GFP in PBMCs, showing prolonged high level GFP expression in approximately 20% of PBMCs (84-94% of CD14+ cells). However, CD14lo expressing cells were not infected as readily as CD14hi expressing cells, but did show some GFP expression by 72 hpi. CD3+ cells were not infected nearly as readily as CD14+ cells; however 3.2 to 3.9% of PBMCs (6-8% of CD3+ cells) were infected and expressed a high level of GFP (Fig. 5) .
The adherent cell fraction of PBMCs is highly permissive for TPV-GFP infection
In order to correlate the previous FACS data to viral replication, CD14+ cells and lymphocytes were separated using an adherence step. Additionally, to investigate the roles of activation and differentiation in viral replication, monocytes were cultured for 7 days to allow for differentiation into macrophages (Andreesen et al., 1990) and PBLs were activated with PHA. These cells were infected at an MOI of 3 and virus was collected at various time points (Fig. 6) . Neither activated nor naive PBLs were able to support TPV-GFP replication by 72 hpi (data not shown). However, the TPV-GFP replication kinetics were extremely robust in the freshly isolated monocytes as compared to either OMK or pHDF cells. TPV-GFP grew to yields of approximately 2.5 orders of progeny increase by 24 hpi, which is essentially the maximum since the amount of virus was similar to that obtained at 72 hpi. Interestingly, macrophages failed to support TPV-GFP replication (Fig. 6 ).
Discussion
It is thought that TPV is primarily transmitted from an unknown animal reservoir to humans by biting insects. Therefore, upon infection, the virus has access to cells of the blood and skin adjacent to the area of the bite. However, the virus rarely causes more than 2 or 3 external skin nodules, and in 80% of infections, there is only a single lesion detected (Jezek et al., 1985) . It is unknown why TPV is unable to cause clinically significant, systemic infection in contrast to certain other orthopoxvirus counterparts, like monkeypox. This study analyzes TPV tropism and replication efficiency in primary human cells to establish an ex vivo model to study TPV cellular tropism in man. TPV expressing GFP was constructed as a tool to examine the ability of TPV various primary human cell types. At an optimal temperature of 33-35°C, we found that TPV-GFP was able to replicate efficiently in pHDFs that were in an exponential growth phase. However, cell cycle blockade either by contact-mediated growth inhibition or treatment with rapamycin, created an intracellular environment that did not allow for efficient TPV replication. Analysis of the permissive cells of the blood suggests that monocytes are the primary cellular vehicle for spread of the virus to secondary sites.
Despite previous reports stating that TPV grows well at 37°C (Mediratta and Essani, 1999) , TPV seems to be somewhat sensitive to temperatures above 35°C. This sensitivity is more obvious when using the TPV-GFP clones, likely due to overexpression of GFP causing cell stress. This effect is not seen at the lower temperatures tested. The implications of this temperature sensitivity may help explain the self-limiting pathogenesis of the TPV in man. In primates, including humans, TPV causes only a few lesions that tend to regress over several weeks. It is possible that this is primarily due to an inefficiency of TPV spread internally due to a higher core body temperature, especially considering the nature of the typical TPV-associated febrile illness. As a result, the virus may be restricted to replicating efficiently only at the periphery.
Lack of efficient systemic viral spread notwithstanding, monocytes from the adherent fraction of PBMCs are highly permissive to TPV infection. The observed rapid replication within the primary human monocytes may allow some spread of TPV in naturally occurring infections, and their infection may also be the cause of the pro-inflammatory cytokines that drive acute febrile illness associated with TPV disease. Additionally, traffic of infected monocytes to the draining lymph node is likely the main culprit in inducing local lymphadenopathy. VACV has been characterized to also primarily infect monocytes (Sanchez-Puig et al., 2004) . However, VACV was also found to infect a proportion of T-cells, B-cells, and NK cells (Sanchez-Puig et al., 2004) . Interestingly, other groups have demonstrated that activated CD3+ leukocytes are productively infected by VACV but resting naive T-cells are poorly infected due to some restriction of either binding or entry (Chahroudi et , 2005) . It is likely that active replication in some population of circulating lymphocytes may be required for the systemic spread of poxviruses in general. In the case of TPV, a small percentage of human CD3+ leukocytes are consistently infected, as measured by GFP expression. However, the failure to support TPV replication as measured by an absence of increase in progeny virus suggests that this is not a productive TPV infection in T-cells, even in lymphocytes activated with PHA. Other subsets of mononuclear cells may be infected but not to any significant degree since CD14-infected cells only represent approximately 3% of cells, similar to the fraction of Tcells that are infected.
pHDFs were used to model TPV infection at the skin. While infection in cycling pHDFs resulted in the production of progeny TPV, cells that were cell cycle arrested only poorly supported viral replication. The effects of cell cycle arrest through contact inhibition or rapamycin treatment, however, were not identical. Either treatment alone caused the accumulation of cells in G1; however, upon TPV infection, cells arrested through contact inhibition progressed into S phase but seemed to be blocked during DNA synthesis, which resulted in accumulation of cells in S phase. This corresponds to the viral replication kinetics since TPV replication paralleled that of the actively dividing cell population until 48 hpi. Once the cells had finished accumulating in S phase, the viral titer remained unchanged for the remainder of the time course experiments. Perhaps even more striking were the detrimental effects on viral gene expression and spread of TPV due to cell cycle arrest. Virus spread to neighboring cells still occurred during these experiments, thus it is likely that the depression of viral gene expression simply slows the replication of the virus and does not block replication at a particular stage.
In contrast, rapamycin treated pHDFs showed evidence of only minimal TPV replication and most cells remained in G1 throughout the experiment indicating effective G1 arrest by the drug. As a consequence, the TPV replication curve was delayed, before reaching the same low-level of TPV progeny observed with quiescent pHDFs. This is an interesting result, considering the opposite effect that rapamycin has on the replication of myxoma virus in human cancer cell lines (Stanford et al., 2007) . This difference is likely due to the altered cell cycle and intracellular signaling milieu in tumor cells, and to the differing cellular requirements of these two poxviruses.
The restricted tropism of TPV to non-quiescent fibroblasts and monocytes gives significant clues into the modest pathogenicity of this virus in man. Without significant amplification of TPV within lymph node T cells, there is little of an internal cellular reservoir of virus to cause significant secondary viremia and delivery of virus to secondary skin sites, resulting in secondary pock formation. In addition, TPV replication in monocytes likely results in the acute febrile illness frequently reported early in TPV infection, and the viral temperature sensitivity may indicate that efficient virus replication occurs only at the periphery. In contrast, the more complex and devastating systemic effects of the more highly pathogenic poxviruses in man, like monkeypox virus and variola virus, are likely tied to their unique ability to replicate and spread within internal lymphocyte reservoirs of the infected host.
Materials and methods
Cells and media
Owl monkey kidney (OMK) cells were obtained from ATCC (CRL-1556) and were maintained in Eagle's minimum essential medium with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate, 100 U penicillin/ml, 100 μg streptomycin/ml, and 10% fetal bovine serum. Neonatal primary human dermal fibroblasts (pHDFs) were obtained from Cascade Biologics and were maintained in medium 106 with low serum growth supplement as recommended by the supplier (Cascade Biologics). pHDFs were cultured no more than 16 population doublings. Human peripheral blood mononuclear cells (PBMCs) were isolated by venous puncture of normal healthy donors and separated on Histopaque-1077 (Sigma). The PBMC layer was removed and washed 3 times in PBS and maintained in RPMI 1640 with 2m ML-glutamine, 100 U penicillin/ml, 100 μg streptomycin/ ml, and 20% fetal bovine serum (Complete RPMI). All cells were grown at 37°C. Quiescence in HDFs was induced by allowing cells to grow to confluence and then cultured at least two more days. Growing cells were infected at approximately 50% confluence to ensure that all cells were actively growing. In some experiments, growing cells were pretreated with 20 mM rapamycin (Sigma) for 16 h. In addition, rapamycin was replaced each time the medium was replaced.
Cell separation and preparation
To isolate monocyte and lymphocyte fractions from PBMCs, freshly isolated cells were allowed to adhere to surface modified cell culture dishes (Becton Dickinson Primaria) for 2 h at 37°C. Peripheral blood lymphocytes (PBLs) were gently washed off with PBS and collected by centrifugation at 300×g. Monocytes remained attached to the cell culture dish surface. To activate PBLs, they were treated with 1 μg/ml phytohemagglutinin (Sigma) for 24 h. They were then collected by centrifugation and washed 3 times with complete medium. Monocytes were left in culture for 7 days in complete RPMI media to allow for differentiation into macrophages. The medium was changed every 2 days.
Generation of TPV expressing EGFP
To produce a TPV construct that expressed EGFP under a synthetic early/late promoter, sequences flanking the intergenic region between 5L and 6L were amplified from genomic DNA from TPV-Kenya using the following primer pairs: 5′-GAATT-CCTTTATACAAAAATAAATGAGTG-3′ (EcoRI underlined), 5′-CTCGAGATTAAACGTACGCACCCG-3′ (XhoI underlined), and 5′-CTGCAGTGCTCCGTGTGATAACAATG-3′ (PstI underlined), 5′-CTGCAGGATAAGTTTTTTAACAATTG-3′ (PstI underlined). The PCR products were cloned into pGEM-T easy (Promega) and sequenced. These constructs were amplified and cloned into pBluescript flanking an EGFP cassette under the synthetic early/late promoter to produce pBS:TPV-GFP.
OMK cells were infected with TPV (strain Kenya) at an MOI of 0.1 and then transfected with pBS:TPV-GFP. Infected cells were collected after 72 h and subjected to 3 cycles of freeze/ thaw and sonication. Virus was plaque purified on OMK cells by picking green fluorescent foci over 5 rounds. TPV-GFP was amplified and determined to be pure by PCR of genomic DNA.
TPV replication curves
Single step replication curves were performed by infecting cells in serum free medium at an MOI of 3 at 27°C for 1 h except for infection of PBMCs, which was done at 37°C. Virus inoculum was removed and replaced with complete medium; this was considered time 0. Multistep replication curves were performed similarly except infecting cells at an MOI of 0.01 instead of 3. Medium was replaced at day 4 of the multistep replication curve to ensure adequate nutrients. Incubators were calibrated immediately before the experiment and temperature was monitored continuously throughout the experiments. Cells were collected as the specified time points and frozen. Virusinfected cells were subjected to 3 cycles of freeze/thaw and were then sonicated to release virus. Cell lysates were used to determine virus titer OMK cells in triplicate. Fluorescent foci were enumerated and graphed using Excel software (Microsoft).
